Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Laboratorios Leti, S.L.
ClinicalTrials.gov Identifier:
NCT01734265
First received: November 22, 2012
Last updated: January 28, 2014
Last verified: November 2012
  Purpose

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.


Condition Intervention Phase
Allergy
Rhinitis
Rhinoconjunctivitis
Seasonal Asthma
Drug: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)
Drug: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective, Open Uncontrolled Study to Evaluate the Safety of Depigoid With Two Pollen Combinations (Grasses/Olea and Grasses/Parietaria)2000DPP/ml in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Seasonal Asthma.

Further study details as provided by Laboratorios Leti, S.L.:

Primary Outcome Measures:
  • immediate or delayed systemic reaction of grade 2 or higher during the treatment period [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    The primary variable in this study is the number of subjects [%] who experienced at least one immediate or delayed systemic reaction of grade 2 or higher during the treatment period.


Secondary Outcome Measures:
  • immediate and/or delayed systemic reactions and immediate and/or delayed local reactions [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

    Number of subjects [%] suffering immediate and/or delayed systemic reactions broken down by grade (EAACI classification).

    • Number of subjects [%] suffering immediate and/or delayed local reactions broken down by diameter (< 5 cm, 5-10 cm or > 10 cm).
    • Number of immediate and/or delayed systemic reactions broken down by grade (EAACI classification).
    • Number of immediate and/or delayed local reactions broken down by diameter (< 5 cm, 5-10 cm and > 10 cm).
    • (Immunology assessment):Measurement of the following immunological parameters: sIgE and sIgG4 at baseline and at the end of the study (after two maintenance doses).


Enrollment: 63
Study Start Date: November 2012
Study Completion Date: April 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)
Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
Drug: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)
Experimental: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
Drug: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)

Detailed Description:

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later. The treatment period consists, thus, of 4 weeks.

Primary variable:

•Number of subjects [%] suffering at least one immediate or delayed systemic reaction of grade 2 or higher during the 4-weeks treatment period [grading according to the 2006 EAACI standards

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has dated and signed the informed consent.
  • Men and women between 18 and 60 years of age (both inclusive).
  • Individuals suffering symptoms of allergic rhinoconjunctivitis or rhinitis during at least the preceding year, with or without allergic seasonal asthma caused by a clinically relevant sensitization to pollens (grasses AND P. judaica or O. europaea). Asthmatic patients can be included in the trial only if seasonal asthma is controlled with a medium daily dose minor or equal to 800 μg/day of budesonide or an equivalent or minor or equal to 400 μg/day of budesonide or an equivalent plus a long-acting- β2 agonist.
  • Asthmatic patients must be stable within 3 months prior to Visit 1 and on an stable inhaled steroid dose within 6 weeks prior to visit 1 and throughout the study. FEV1 must be ≥ 80% of predicted value.
  • The IgE-mediated sensitization must be demonstrated by the following:

medical history AND IgE specific CAP RAST ≥ 2 to the suspected relevant pollens (grass pollen AND Olea and/or Parietaria) AND a positive skin prick test to grass and Olea and/or Parietaria.

Exclusion Criteria:

  • Any contraindication for treatment with allergen specific immunotherapy.
  • Forced expiratory volume in 1 s (FEV1) or peak expiratory flow (PEF) value <80% of the predicted normal value.
  • Clinically relevant allergy symptoms due to sensitization to perennial allergens (mites, molds, epithelia) or other seasonal pollen which might interfere with the safety of the IMP.
  • Asthma requiring a dose > 800 μg/day of Budesonide or an equivalent, without long-lasting beta-2 agonists or requiring a dose > of 400 μg/day of Budesonide or an equivalent plus a long-acting-β2 agonist to reach asthma control, according to the Global Initiative for Asthma (GINA 2010)
  • Patients with non controlled bronchial asthma within 3 months prior to Visit 1.
  • Patients with asthma who have been treated with systemic steroids within 3 months prior to V1.
  • Patients with hospital admission due to asthma exacerbations within 1 year prior to V1.
  • Acute or chronic inflammatory or infectious diseases of the airways.
  • Chronic structural diseases of the respiratory system (for example, emphysema or bronchiectasis).
  • Immune system diseases, both autoimmune diseases and immunodeficiency.
  • Any disease involving a contraindication for the use of adrenaline (for example, hyperthyroidism).
  • Serious uncontrolled diseases involving a risk for the subjects participating in this study
  • Malignant disease with activity in the last 5 years.
  • Excessive consumption of alcohol, drugs or medication.
  • Serious psychiatric, psychological or neurological disorders.
  • Systemic or topical treatment with beta-blocker drugs 1 week before visit 2.
  • Treatment with substances interfering with the immune system 2 weeks before visit 2.
  • Use of tricyclic, tetracyclic and IMAO antidepressants. It will not be allowed to wash up antidepressants to enter the study because of the risks of interrupting antidepressant treatment, so patients on antidepressants therapy cannot be included in the trial.
  • Use of systemic corticosteroids 3 months before visit 1.
  • Immunization with prophylactic (bacterial or viral) vaccines within 7 days before visit 1 (prophylactic vaccines are allowed during the administration of IMP period provided they are administered at least one week after IMP administration and the next IMP administration is administered at least 14 days later).
  • Participation of the subject in another clinical trial 30 days before visit 2
  • Subjects who are going to donate stem cells, blood, organs or bone marrow in the course of the study.
  • Female subjects who are pregnant or nursing and women with a positive pregnancy test at visit 1 or 2.
  • Women of childbearing potential not using highly effective methods of birth control.
  • Subjects who are unable to comply with the requirements of the study or who in the opinion of the investigator should not participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01734265

Locations
Spain
H. Manresa
Manresa, Barcelona, Spain, 08243
H. Luis Alcañiz
Xativa, Valencia, Spain, 46800
H. Virgen del Rocío
Sevilla, Spain, 41013
H. Virgen Macarena
Sevilla, Spain, 41009
Sponsors and Collaborators
Laboratorios Leti, S.L.
Investigators
Principal Investigator: Pedro Guardia, Dr H. Virgen Macarena
Principal Investigator: Joaquín Quiralte, Dr H. Virgen del Rocío
Principal Investigator: Luis Angel Navarro, Dr H. Luis Alcañiz
Principal Investigator: Santiago Nevot, Dr H. Manresa
  More Information

No publications provided

Responsible Party: Laboratorios Leti, S.L.
ClinicalTrials.gov Identifier: NCT01734265     History of Changes
Other Study ID Numbers: 6078-PG-PSC-193, 2012-001699-12
Study First Received: November 22, 2012
Last Updated: January 28, 2014
Health Authority: Spain: Spanish Agency of Medicines

Additional relevant MeSH terms:
Asthma
Conjunctivitis
Rhinitis
Bronchial Diseases
Conjunctival Diseases
Eye Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on November 19, 2014